Medtronic (MDT) is reportedly looking at adjusting its global manufacturing footprint amid heightened concerns that the U.S.

Medical device maker Medtronic is looking at options to modify its global manufacturing footprint as part of efforts to ...

Medtronic said Monday the U.S. Food and Drug Administration has approved an adaptive brain-stimulation device as a treatment ...

After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive ...

The biggest technical challenge for adaptive deep brain stimulation (aDBS) is how small brain signals are, Medtronic's Scott ...

In a welcome move, Medtronic stock saw its Relative Strength Rating improve from 67 to 73 on Tuesday. Please watch the video ...

The neurovascular market, estimated at $4.2bn in 2024 by GlobalData, is becoming increasingly specialised and competitive.

The FDA has approved BrainSense, an adaptive deep brain stimulation system that can adjust therapy for Parkinson’s disease in real time based on the patient’s brain activity, according to the ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Medtronic's agnostic approach to global challenges, including tariffs and AI, ensures success and innovation in healthcare ...

A series of important developments in the healthcare sector includes Medtronic adapting to tariff threats, Hims & Hers facing ...

The company, whose products range from insulin pumps to surgical robots, has been closely monitoring Trump's tariff plans due to its presence in Mexico.